AGTC to Present at Cell & Gene Meeting on the Mediterranean
April 14 2022 - 08:00AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical
stage biotechnology company focused on the development of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare and debilitating diseases with an initial focus on
inherited retinal diseases (IRDs), today announced that Sue Washer,
President & Chief Executive Officer, will present at the
Alliance for Regenerative Medicine Cell & Gene Meeting on the
Mediterranean in Barcelona, Spain on Thursday, April 21 at 9:30 PM
CEST / 3:30 PM ET.
Please visit www.meetingonthemed.com for full
information including registration and to view a recording of the
presentation, which will be available within 24 hours at its
conclusion.
About AGTCAGTC is a
clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and
central nervous system (CNS) diseases. AGTC is a leader in
designing and constructing all critical gene therapy elements and
bringing them together to develop customized therapies with the
potential to address unmet patient needs. AGTC’s most advanced
clinical programs leverage its best-in-class technology platform to
potentially improve vision for patients with inherited retinal
diseases. AGTC has active clinical trials in X-linked retinitis
pigmentosa (XLRP) and achromatopsia (ACHM CNGB3). Its preclinical
programs build on the company’s industry leading AAV manufacturing
technology and scientific expertise. AGTC is advancing multiple
important pipeline candidates to address substantial unmet clinical
needs in optogenetics, otology and CNS disorders, and has strategic
collaborations with companies including Bionic Sight, an innovator
in the emerging field of optogenetics, and retinal coding and
Otonomy, Inc., a biopharmaceutical company dedicated to the
development of innovative therapeutics for neurotology. For more
information, please visit https://agtc.com/.
IR/PR Contacts:David
Carey (IR)Lazar FINN PartnersT: (212)
867-1768david.carey@finnpartners.com
Corporate Contact:Jonathan LieberChief
Financial OfficerApplied Genetic Technologies CorporationT: (617)
843-5778jlieber@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2023 to Mar 2024